Insider Trading Alert - DLX, MDSO And IPGP Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Friday, May 15, 2015, 111 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,266.50 to $281,749,912.50.

Highlighted Stocks Traded by Insiders:

Deluxe (DLX) - FREE Research Report

Baldwin Ronald C, who is Director at Deluxe, sold 3,000 shares at $64.40 on May 15, 2015. Following this transaction, the Director owned 19,341 shares meaning that the stake was reduced by 13.43% with the 3,000-share transaction.

The shares most recently traded at $64.62, up $0.22, or 0.34% since the insider transaction. Historical insider transactions for Deluxe go as follows:

  • 4-Week # shares sold: 5,877
  • 12-Week # shares sold: 5,877
  • 24-Week # shares sold: 23,496

The average volume for Deluxe has been 350,200 shares per day over the past 30 days. Deluxe has a market cap of $3.2 billion and is part of the services sector and diversified services industry. Shares are up 3.9% year-to-date as of the close of trading on Friday.

Deluxe Corporation provides checks, forms, marketing solutions, accessories, and other products and services for small businesses and financial institutions. It operates through three segments: Small Business Services, Financial Services, and Direct Checks. The stock currently has a dividend yield of 1.86%. The company has a P/E ratio of 16.4. Currently, there are no analysts who rate Deluxe a buy, 1 analyst rates it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DLX - FREE

TheStreet Quant Ratings rates Deluxe as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Deluxe Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Medidata Solutions (MDSO) - FREE Research Report

Hirschfeld Steven Isaac, who is Chief Commercial Officer at Medidata Solutions, sold 22,153 shares at $53.36 on May 15, 2015. Following this transaction, the Chief Commercial Officer owned 36,383 shares meaning that the stake was reduced by 37.85% with the 22,153-share transaction.

The shares most recently traded at $56.10, up $2.74, or 4.89% since the insider transaction. Historical insider transactions for Medidata Solutions go as follows:

  • 4-Week # shares bought: 2,400
  • 4-Week # shares sold: 40,000
  • 12-Week # shares bought: 2,400
  • 12-Week # shares sold: 40,000
  • 24-Week # shares bought: 2,400
  • 24-Week # shares sold: 74,020

The average volume for Medidata Solutions has been 473,500 shares per day over the past 30 days. Medidata Solutions has a market cap of $3.0 billion and is part of the technology sector and computer software & services industry. Shares are up 12.29% year-to-date as of the close of trading on Friday.

Medidata Solutions, Inc. provides cloud-based clinical development solutions for life sciences in the United States and internationally. The company offers applications and data analytics for clinical development. The company has a P/E ratio of 383.0. Currently, there are 7 analysts who rate Medidata Solutions a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MDSO - FREE

TheStreet Quant Ratings rates Medidata Solutions as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, robust revenue growth, good cash flow from operations, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Medidata Solutions Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

IPG Photonics (IPGP) - FREE Research Report

Gapontsev Valentin P, who is CEO & Chairman of the Board at IPG Photonics, sold 5,000 shares at $95.09 on May 15, 2015. Following this transaction, the CEO & Chairman of the Board owned 285,331 shares meaning that the stake was reduced by 1.72% with the 5,000-share transaction.

The shares most recently traded at $97.60, up $2.51, or 2.57% since the insider transaction. Historical insider transactions for IPG Photonics go as follows:

  • 4-Week # shares sold: 15,100
  • 12-Week # shares sold: 68,675
  • 24-Week # shares sold: 348,601

The average volume for IPG Photonics has been 425,800 shares per day over the past 30 days. IPG Photonics has a market cap of $5.1 billion and is part of the technology sector and electronics industry. Shares are up 26.82% year-to-date as of the close of trading on Friday.

IPG Photonics Corporation develops and manufactures a range of high-performance fiber lasers, fiber amplifiers, and diode lasers used in various applications, primarily in materials processing worldwide. The company has a P/E ratio of 23.6. Currently, there are 6 analysts who rate IPG Photonics a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on IPGP - FREE

TheStreet Quant Ratings rates IPG Photonics as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full IPG Photonics Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

The President Must Show 'America First' Isn't 'America Alone': Market Recon

The President Must Show 'America First' Isn't 'America Alone': Market Recon

Here's Why Business Owners Face Extra Challenges in Small Cities

Here's Why Business Owners Face Extra Challenges in Small Cities

Market Recon: The Tax Reform Is Just Ordinary Negotiation on Steroids

Market Recon: The Tax Reform Is Just Ordinary Negotiation on Steroids

Market Recon: Let's Talk About Bonds for a Minute

Market Recon: Let's Talk About Bonds for a Minute

Here's Why This Rally Is Sustainable: Cramer's 'Mad Money' Recap (Tuesday 1/24/17)

Here's Why This Rally Is Sustainable: Cramer's 'Mad Money' Recap (Tuesday 1/24/17)